期刊文献+

胆固醇7α-羟化酶在胆汁淤积中的调节机制研究进展 被引量:5

Research progress on regulatory mechanisms of cholesterol 7α-hydroxylase in cholestasis
下载PDF
导出
摘要 胆汁淤积是由多种原因所致的胆汁酸异常积聚,临床表现为黄疸或黄斑瘤等。胆固醇7α-羟化酶(cholesterol 7α-hydroxylase,CYP7A1)是体内催化胆固醇合成胆汁酸的限速酶,其活性与胆汁酸的合成量密切相关。机体中由法尼酯衍生物X受体(FXR)介导的法尼酯衍生物X受体/小异二聚体伴侣(FXR/SHP)信号通路和法尼酯衍生物X受体/成纤维细胞因子19/成纤维生长因子受体4(FXR/FGF19/FGFR4)信号通路以及由孕甾烷X受体(PXR)介导的信号通路是重要的胆固醇7α-羟化酶调节路径。上述通路通过调节胆固醇7α-羟化酶的活性,调控胆汁酸的合成,进而维持胆汁酸的内平衡。本文就近年来有关胆汁淤积中胆固醇7α-羟化酶的调节机制研究进行综述,为探索临床治疗胆汁淤积的靶点提供了参考。 Cholestasis is an abnormal accumulation of bile acids caused by various causes,and the clinical manifestations are jaundice or macular tumors.Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme which catalyzes the synthesis of bile acids from cholesterol.Its activity is closely related to the amount of bile acid synthesis.FXR-mediated FXR/SHP signaling pathway and FXR/FGF19/FGFR4 signaling pathway,and PXR-mediated signaling pathway are important CYP7A1 regulatory pathways in vivo.The above signaling pathways regulate the synthesis of bile acids by regulating the activity of CYP7A1,thus maintain the internal balance of bile acids.This review introduced the research progress of regulatory mechanisms of CYP7A1 in cholestasis in recent years,and provided references for exploring the targets of clinical treatment of cholestasis.
作者 李会涛 林以宁 LI Huitao;LIN Yining(School of Chinese Medicine,China Pharmaceutical University,Nanjing 211198,China)
出处 《药学研究》 CAS 2019年第2期91-94,共4页 Journal of Pharmaceutical Research
基金 国家自然科学基金(No.81573836) 江苏省自然科学基金(No.BK20151440)
关键词 胆汁淤积 法尼酯衍生物X受体 孕甾烷X受体 胆固醇7Α-羟化酶 调节机制 Cholestasis FXR PXR CYP7A1 Regulatory mechanism
  • 相关文献

参考文献6

二级参考文献116

  • 1朱振家,钱之玉,包晨颖.京尼平苷对地鼠胆固醇结石形成的影响[J].中草药,2001,32(6):530-532. 被引量:14
  • 2陈辉扬,陈军,温平康.茵栀黄注射液的药理作用与临床应用评价[J].药品评价,2005,2(2):122-124. 被引量:27
  • 3胡中伟,郭家伟,邓西龙.非酒精性脂肪肝与血清瘦素和胰岛素抵抗关系[J].南方医科大学学报,2006,26(6):853-855. 被引量:10
  • 4兰绍阳,佘世锋.茵陈对肝内胆汁淤积湿热证大鼠利胆退黄作用机制的研究[J].时珍国医国药,2012,23(7):1127-1130.
  • 5Corpechot C,Chazouilleres O,Poupon R.Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome[J].J Hepatol,2011,55(6):1361-7.
  • 6Makishima M,Okamoto A Y,Repa J J,et al.Identification of a nuclear receptor for bile acids[J].Science,1999,284(5418):1362-5.
  • 7Jonker J W,Liddle C,Downes M.FXR and PXR:potential therapeutic targets in cholestasis[J].J Steroid Biochem Mol Biol,2012,130(3-5):147-58.
  • 8Fiorucci S,Clerici C,Antonelli E,et al.Protective effects of 6-ethyl chenodeoxycholic acid,a farnesoid X receptor ligand,in estrogen-induced cholestasis[J].J Pharmacol Exp Ther,2005,313(2):604-12.
  • 9Fiorucci S,Antonelli E,Rizzo G,et al.The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis[J].Gastroenterol,2004,127(5):1497-512.
  • 10Fickert P,Zollner G,Fuchsbichler A,et al.Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles[J].Gastroenterol,2002,123(4):1238-51.

共引文献49

同被引文献66

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部